Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | PIK3R5 | Q8WYR1 | 1/20 | 0.41 |
| ▸ | PIK3R3 | Q92569 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | MERTK | Q12866 | 1/20 | 0.41 |
| ▸ | DTYMK | P23919 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2553864 | 0.95 | KDM4E (0.46) | KDM4EPKMFPR2GPR119PIK3CD | |
| SCHEMBL2556694 | 0.90 | ACKR3 (0.45) | FPR2BACE1KDM1A | |
| SCHEMBL2554249 | 0.86 | ACKR3 (0.45) | BACE1KDM1A | |
| SCHEMBL2550969 | 0.80 | ROCK1 (0.46) | KDM4ETP53 | |
| SCHEMBL2556796 | 0.75 | TACR3 (0.46) | KDM4ETP53 | |
| SCHEMBL27402508 | 0.75 | GPR119 (0.54) | KDM4EPKMFPR2GPR119BACE1 | |
| SCHEMBL2557120 | 0.74 | CCR3 (0.46) | — | |
| SCHEMBL1995835 | 0.74 | KDM4E (0.46) | KDM4EPKMGPR119PIK3CDPIK3R2 | |
| SCHEMBL31402474 | 0.74 | KDM4E (0.50) | KDM4EPKMFPR2GPR119KDM1A | |
| SCHEMBL12635860 | 0.72 | KDM4E (0.56) | KDM4EPKMFPR2GPR119BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9655906-B2 | Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-05-23 | — | — | US | disclosed |
| US-20150320763-A1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F S.P.A. (IT) | 2015-11-12 | — | — | US | disclosed |
| US-9120801-B2 | Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2015-09-01 | — | — | US | disclosed |
| EP-2556074-B1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | ACRAF (IT) | 2015-01-21 | — | — | EP | disclosed |
| EP-2556074-A1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO - A.C.R.A.F. - S.p.A. (IT) | 2013-02-13 | — | — | EP | disclosed |
| US-20130023524-A1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R. (IT) | 2013-01-24 | — | — | US | disclosed |
| WO-2011124430-A1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023524-A1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | CYP3A43, CYP3A4, CYP3A5 | KDM4E 3845/4885PKM 559/4885FPR2 2291/4885 |
| US-20150320763-A1 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | CYP3A43, CYP3A4, CYP3A5 | KDM4E 3845/4885PKM 559/4885FPR2 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.